Drug intelligence / Profile preview

[99mTc]Tc-Soluplus + d-alpha-tocopheryl polyethylene glycol succinate

Development stage: Preclinical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

[99mTc]Tc-Soluplus + d-alpha-tocopheryl polyethylene glycol succinate is a radiolabeled nanodiagnostic agent developed for preclinical molecular imaging in oncology. It consists of polymeric micelles formed by the combination of Soluplus, a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, and d-alpha-tocopheryl polyethylene glycol succinate (TPGS), which are subsequently radiolabeled with the gamma-emitting radioisotope Technetium-99m ([99mTc]Tc). This radionanoprobe (RNP) is designed to characterize biological processes associated with the diagnosis and monitoring of breast and colon cancers in animal models. The micellar structure provides a stable delivery vehicle for the radioisotope and can be further functionalized with targeting ligands, such as glucose or bevacizumab, to enhance specificity toward tumors expressing GLUT1 or VEGFR, respectively.

Other names: 99mTc-Soluplus-TPGS micelles99mTc-labeled Soluplus-TPGS nanoprobes99mTc-Soluplus-TPGS RNPs

Targets

GLUT1 (Glucose transporter 1)VEGFR (VEGFR family)

Beyond the preview

Go deeper on [99mTc]Tc-Soluplus + d-alpha-tocopheryl polyethylene glycol succinate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [99mTc]Tc-Soluplus + d-alpha-tocopheryl polyethylene glycol succinate.

Explore the full profile